Dyne Therapeutics announced the pricing of an upsized underwritten public offering of its common stock at $18.44 per share.
The gross proceeds from the offering are expected to be $350.0 million.
The offering is expected to close on or about December 11, 2025.
Public Offering Details
Pricing of 18,980,478 shares at $18.44 per share with expected gross proceeds of $350.0 million.
Underwriters
Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.
Option for Additional Shares
Underwriters granted a 30-day option to purchase up to an additional 2,847,071 shares at the offering price.
- Dyne aims to deliver functional improvement for individuals with neuromuscular diseases by focusing on therapeutics targeting muscle and the central nervous system.
- The successful pricing of the public offering indicates investor confidence in Dyne's mission and potential for future growth.
Dyne Therapeutics' upsized public offering reflects a significant step in funding their mission to address genetically driven neuromuscular diseases.